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Running head:  
ART impact on liver in HIV+ Zambians 
 
Brief summary of the paper’s main point: 
HIV-infected Zambian adults had reduced liver stiffness after initiation of tenofovir-containing 
antiretroviral therapy, regardless of hepatitis B virus (HBV) coinfection. Despite good early virological 
and serological response to therapy, HBV coinfected patients had increased odds of significant 
fibrosis/cirrhosis at follow-up.   
  
Abstract: 
 
Background: 
We investigated changes in hepatic fibrosis, based on transient elastography (TE), among HIV-infected 
patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia. 
 
Methods: 
Patients’ liver stiffness measurements (LSM; in kiloPascals [kPa]) at ART initiation were categorized as 
no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE 
was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen 
positive at baseline), we described LSM change and the proportion with an increase/decrease in 
fibrosis category. Using multivariable logistic regression we assessed correlates of significant 
fibrosis/cirrhosis at 1 year on ART.  
 
Results: 
Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were 
women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received 
tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. 
The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with 
and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% 
(P<0.001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 
year (all P<0.05).  
 
Conclusion: 
The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant 
fibrosis/cirrhosis decreased following ART initiation  regardless of HBV status. This suggests that HIV 
infection plays a role in liver inflammation. HBV coinfected patients were more likely to have significant 
fibrosis/cirrhosis at 1 year on ART.  
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Background: 
 
Among HIV-infected individuals, liver-related mortality is primarily attributed to viral hepatitis 
coinfection;1 however, HIV infection also induces hepatic inflammation and immune activation and 
unsuppressed HIV infection is a risk factor for liver fibrosis progression.2-5 The World Health 
Organization (WHO) and most national guidelines recommend that HIV-hepatitis B virus (HBV) 
coinfected individuals receive an ART regimen containing tenofovir disoproxil fumarate (TDF) because 
the drug is highly potent against both viruses.6,7 Among HIV-negative individuals with chronic HBV 
infection (CHB), TDF not only suppressed HBV replication but also improved liver histology.8 Among 
TDF-treated CHB patients in China, a biphasic pattern of fibrosis regression was described, reflected in 
both liver histology and transient elastography (TE), a non-invasive surrogate of fibrosis/cirrhosis.9  
 
We sought to describe the impact of HBV-active ART on liver stiffness, in a prospective HIV cohort 
study in Zambia, including a subset of individuals with HIV-HBV coinfection. We hypothesized that liver 
stiffness, based on TE, would decrease in the year following ART initiation particularly among those 
with HIV-HBV coinfection. Among HIV-HBV patients, we also aimed to establish the short-term HBV 
virological and serological outcomes of TDF-containing ART. 
 
 
Methods: 
 
IeDEA hepatitis cohort in Zambia 
We established a prospective cohort of HIV-infected adults at two public-sector outpatient primary care 
facilities in Zambia’s capital Lusaka under the framework of the International Epidemiologic Databases 
to Evaluate AIDS (IeDEA) collaboration in Southern Africa.10 Any HIV-infected patient aged 18+ years 
old, treatment naïve, and eligible to initiate ART under national guidelines met the criteria to join the 
cohort.11 The preferred first-line ART regimen consisted of the fixed-dose combination TDF, 
emtricitabine (FTC), and efavirenz (EFV) with abacavir, lamivudine, nevirapine (NVP), and ritonavir-
boosted lopinavir as alternative agents. Baseline was defined as the time of ART initiation and cohort 
characteristics at baseline were previously described.12,13 The ethics committees of the University of 
 Zambia (Lusaka, Zambia) and University of North Carolina at Chapel Hill (North Carolina, USA) 
approved this study (clinicaltrials.gov, NCT02060162). 
 
Study procedures and definitions 
At baseline, we measured ALT (normal was <19 U/L for women and <30 for men), creatinine, CD4+ 
count, tested for HBV and HCV coinfection, assessed alcohol consumption levels, and performed TE. 
HBV coinfection was defined as a positive hepatitis B surface antigen (HBsAg) test by finger prick 
(Determine, Alere, USA) or in serum (Access2Analyzer, Beckman Coulter, USA) and among HBsAg-
positives, we measured serum hepatitis B e-antigen and HBV viral load (Roche COBAS 
AmpliPrep/COBAS Taqman, Pleasanton, California). We used Sanger sequencing to determine HBV 
genotypes14 and screened HIV-HBV patients for hepatitis delta antibodies (ETI-AB-Delta-2, Diasorin, 
Brussels, Belgium). We used a rapid point-of-care antibody test for HCV testing (Oraquick, Orasure, 
USA) and confirmed active infections by measuring HCV RNA in antibody-positives.12 We used the 
Alcohol Use Disorders Identification Test consumption (AUDIT-C) questions to establish alcohol 
consumption levels and defined hazardous drinking as AUDIT-C score 3 for women and 4 for men.15-
18 We measured liver stiffness (in kiloPascals; kPa) by TE (Fibroscan 402, Echosens, Paris, France) in 
non-pregnant patients according to manufacturer guidelines.19,20 Fasting was not required before TE 
but study visits occurred in the mid-morning or early afternoon and most patients had waited 1-4 hours 
without eating before the procedure. TE measurements were considered very reliable if the interquartile 
range divided by median (IQR/M) was <0.1, reliable if IQR/M was 0.1-0.3, and poorly reliable if IQR/M 
was >0.3.21  
 
Follow-up visits for routine ART monitoring occurred at 2, 4, 8, and 12 weeks and every 3 months 
thereafter. At 1 year on ART, we repeated baseline measurements with the exception of HCV testing 
and in addition assessed ART adherence using the medication possession ratio (MPR).22 MPR was 
categorized as optimal (>95%), suboptimal (80-95%), and poor (<85%). During follow-up deaths were 
ascertained by report of the patient’s family/friend, the clinic staff, or a community health worker. 
Transfers to other clinics were documented when a patient informed the staff of their intent to establish 
HIV care at a distant site. We considered a patient lost to follow-up (LTFU) if there were no 
documented clinical or pharmacy visits for at least 6 months and no 1-year visit.  
 
Study outcomes 
Our primary outcome was change in hepatic stiffness based on TE. We categorized each liver stiffness 
measurement (LSM) according to its equivalent Metavir liver fibrosis stage as no/minimal fibrosis (F0-
 F1), significant fibrosis (F2-F3), and cirrhosis (F4), using thresholds that were previously established in 
published comparisons between TE and liver histology. For patients with HIV alone, no/minimal fibrosis 
was LSM <7.1 kPa, significant fibrosis was 7.1-11.0 kPa, and cirrhosis was 11.1 kPa.23 Among HIV-
HBV patients, no/minimal fibrosis was <5.9 kPa, significant fibrosis was 5.9-9.3 kPa and cirrhosis was 
9.4.24 In HIV-HBV patients, we defined HBV virological suppression (VS) as a VL <20 IU/ml. In mid-
2014, Zambian national treatment guidelines incorporated routine HIV viral load monitoring; therefore, a 
subset of the cohort participants also had an HIV VL at 1 year on ART (Roche COBAS 
AmpliPrep/COBAS Taqman, Pleasanton, California). HIV VS was defined as a VL <40 copies/ml.  
 
Statistical analyses 
We excluded from analysis patients without TE at baseline. Among those with baseline TE, we further 
excluded those who died, transferred out, withdrew, became pregnant, or were LTFU during follow-up, 
and those without a repeat TE at 1 year. We compared the demographic and clinical characteristics of 
participants analyzed at the primary outcome with those excluded using the Wilcoxon rank sum test for 
continuous variables and the Chi square test for categorical ones. In the analysis cohort, we compared 
baseline characteristics of patients with HIV alone and those with HIV-HBV using the same tests. We 
graphed the distribution of fibrosis stages at baseline and 1 year and among those with F2 equivalent 
TE at baseline, we analyzed the proportion who experienced a reduction in fibrosis using a McNemar 
test. In bivariable analyses, we considered the following potential correlates of liver fibrosis: age, sex, 
WHO stage, initial CD4+ count, body mass index (BMI), baseline ALT level, HBsAg-positivity, HIV VS 
at 1 year, and hazardous alcohol consumption at 1 year. A stepwise logistic regression model was used 
to identify factors associated with significant fibrosis or cirrhosis (F2-F4) at 1 year with backward 
selection algorithm. The probability of removal was set at 0.2 using likelihood ratio test. As HIV viral 
suppression was an important possible risk factor we maintained that variable in the final model.  
 
Among the subset with HIV-HBV coinfection, we described the effectiveness of ART to suppress HBV 
replication as the median log10 change in HBV VL and the percentage of coinfected individuals with VS 
at 1 year. In bivariable analyses we explored possible correlates of HBV VS including pre-treatment 
HBV VL, HBeAg-positivity, MPR, and HIV VL.  
  
 Results:  
 
Cohort characteristics 
From Oct-2013 to Aug-2014, 798 eligible, HIV-infected adults were enrolled in our cohort. Of these, 45 
(5.6%) died, 19 (2.4%) withdrew or transferred to another facility, and 38 (4.8%) were LTFU during the 
first year on ART. In addition, 29 women were pregnant at either baseline or 1-year visits and could not 
undergo TE. Of the remaining 667 retained to the 1-year visit, 463 (69.4%) had valid TE at both time 
points and comprised the analysis cohort (Figure 1). Patients without TE (n=204) were similar to those 
analyzed in terms of their median age (35 vs. 35 years; P=0.96) and percentage women (53.7 vs. 
53.8%; P=0.98) but had slightly lower baseline CD4 counts (204 versus 240 cells/mm3; P=0.03) and 
higher prevalence of WHO stage 3 or 4 (47.4% versus 36.6%; P=0.01). 
 
Within the analysis cohort (n=463), 61 (13.2%) had HBV, and none had active HCV coinfection (Table 
1). HIV-HBV coinfected individuals were more likely to have hazardous alcohol consumption and had 
higher baseline ALT levels and LSM compared to those with HIV alone (Table 1). Nearly all patients 
(97.6%) received fixed-dose combination TDF, FTC, and EFV. MPR (i.e., ART adherence) at 1 year 
was optimal for 404 (89.8%), suboptimal for 34 (7.6%), and poor for 12 (2.7%). CD4+ counts increased 
by a median of 106 cells/mm3 (interquartile range [IQR], 33-199) from baseline to 1 year. HIV VL was 
available at 1 year for 301 (65.0%) patients and 253 (81.6%) were suppressed. HIV VS was observed 
in 84.1% of patients with optimal 1-year MPR, 66.7% with suboptimal and 25.0% with poor adherence.  
 
Change in liver stiffness 
The median time between baseline and 1-year TE was 11.7 months (95% confidence interval, 11.1-
12.6). Most TE measurements were either very reliable (n=450; 48.6%) or reliable (n=469; 50.6%) and 
very few were poorly reliable (n=7; 0.8%). The median change in LSM was -0.70 kPa (IQR, -1.50 to 
+0.30) and was similar between patients with and without HBV coinfection (-0.7 versus -0.7 kPa; Figure 
2). There was a significant reduction in the proportion with TE suggestive of significant fibrosis (14.0% 
versus 6.7%; P<0.001) or cirrhosis (2.2% versus 1.1%; P=0.01). Among patients with HIV alone, the 
finding of significant fibrosis decreased from 9.2% to 4.5% (P=0.002) while the finding of cirrhosis 
remained consistent (1.2% versus 1.0%; P=0.10). For HIV-HBV coinfected patients, a larger absolute 
reduction was observed for both significant fibrosis (45.9% vs. 21.3%; P=<0.001) and cirrhosis (8.2% 
vs. 1.6%; P=0.04). Among the 65 participants with F2-F4 at baseline, 46 (70.8%) experienced a 
reduction of liver fibrosis by 1 year on ART (Supplementary Table 1). Those with HIV alone appeared 
more likely to experience a reduction compared to HIV-HBV patients but this association was not 
 statistically significant (78.4% versus 60.7%; P=0.12). Other patient factors including as age, sex, CD4+ 
count, baseline ALT, hazardous drinking at 1 year, and HIV VS were not associated with a change in 
fibrosis (Supplementary Table 2), although the numbers in each group were small.  
 
Correlates of significant fibrosis/cirrhosis at 1 year on ART 
In multivariable analysis, men (AOR, 3.13; 95% CI, 1.10-8.93) and patients with HBV coinfection (AOR, 
7.72; 95% CI, 2.89-20.57; Table 2) were more likely to have significant fibrosis/cirrhosis. With each 10-
year increase in age there was an increased odds of the outcome (AOR, 1.81; 1.07-3.07). HIV viral 
suppression by 1 year was not associated with reduced odds of significant fibrosis/cirrhosis (AOR, 0.89; 
95% CI, 0.26-3.04). Neither HBV VL nor HBV genotype (A1 versus E) were associated with 1-year LSM 
among coinfected patients. During follow-up there were 12 patients (2.6%; 10 with HIV alone and 2 with 
HIV-HBV) who experienced progression to a higher disease category.  
 
HBV virological and serological outcomes 
HIV-HBV patients also achieved significant virological control of HBV during the first year of ART. 
Among the 61 coinfected individuals, baseline HBV VL was available for all and 1-year VL was 
available for 51 (83.6%). Median baseline HBV VL was 3.7 log10 IU/ml and 27 (44.3%) had HBV VL 
>4.3 log10 IU/ml (20,000 IU/ml; Table 1). HBV genotypes were A1 for 17 and E for 22 among the 
successfully sequenced samples. Nineteen were HBeAg-positive, 34 were HBeAg-negative, and the 
HBeAg status was not determined in 8 patients. Hepatitis delta antibodies were observed in 2 
individuals. Following one year of ART HIV-HBV coinfected patients experienced a median reduction in 
HBV VL of 4.8 log10 IU/ml and 33 (64.7%) achieved HBV VS (Supplementary Figure 1). HBV VS at 1 
year was more common among patients with optimal adherence compared to those with 
suboptimal/poor adherence (76.5% versus 11.8%; P=0.08). HBeAg-positive patients were less likely to 
have HBV VS (31.3% versus 79.3%; P=0.001). HIV VS at 1 year was not observed to be a significant 
predictor of HBV VS. There was a trend towards lower HBV VL in patients with HIV VS compared to 
those with detectable HIV RNA at 1 year (1.0 versus 0.5 log10 IU/ml; Figure 3), but this did not reach 
statistical significance (P=0.25). Among HBeAg-positives, only 1 of the 14 re-tested (7.1%) experienced 
an HBeAg loss. Of 58 patients with an available Determine HBsAg at baseline and 1 year, 7 (12.1%) 
became HBsAg-negative. Although the absolute numbers were small, patients with HBsAg loss tended 
to be female (71.4% versus 43.1%) and slightly younger (median age 28.4 versus 36.4 years) 
compared to those who remained HBsAg-positive. Median pre-treatment HBV VL was 6.7 log10 IU/ml 
among those with HBsAg loss and 3.7 log10 IU/ml among those without HBsAg loss.  
 
 Discussion: 
 
During the first year of ART in Zambia, the percentage of HIV-infected Zambian adults with elevated 
liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation   
regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HIV-HBV 
patients had a good early viral response to ART; however, this group continued to have higher levels of 
liver fibrosis markers at 1 year on therapy. These data support recommendations for HBsAg testing, 
early ART initiation, and close monitoring of liver disease in this at-risk group. 
 
Our results provide further evidence on the benefits of effective ART on virological and clinical 
outcomes in HIV and HIV-HBV coinfection, especially regimens containing potent HBV activity such as 
provided by TDF. In line with previous reports from Europe and Africa, we observed that taking ART 
was associated with reductions in liver fibrosis markers in those with HIV alone and HIV-HBV 
coinfection. Improvement in liver fibrosis was also reported in patients with CHB in Europe8 and HIV-
HBV coinfection25 who received TDF. Among 348 CHB patients in Europe, 176 (51%) had histological 
regression of fibrosis over 5 years of TDF.8 In Ghana, over 3 years of TDF-containing ART, the 
proportion of HIV monoinfected (30.8% to 21.8%) and HIV-HBV coinfected individuals (56.4% to 38%) 
with elevated LSM reduced significantly.3  
 
At 1 year, we observed that increasing age, male sex, and HBV coinfection were associated with 
persistently elevated LSM suggestive of significant fibrosis/cirrhosis. This is consistent with other 
studies in the published literature. Increasing age and male sex have been shown to be a potential co-
factors for liver fibrosis progression.26,27 We did not find an association between hazardous drinking and 
TE at 1 year but quantifying alcohol consumption by self-report alone can be difficult and is subject to 
underreporting.28 Similar to our findings, 44 of 76 (57.9%) HIV-HBV coinfected Ghanaians had 
persistent elevations in LSM (>5.9 kPa) after switching from non-TDF to TDF-containing ART.25 This 
may reflect that these patients have a larger amount of disease before ART, incomplete HBV viral 
suppression (as was observed in our study), or that TE measurements may be elevated by 
inflammation as well as fibrosis. We suspect that with additional follow-up LSM will continue to improve 
in the setting of ART-treated HIV-HBV, as shown for CHB patients in China.9   
 
We also generated data on the short-term effectiveness of TDF-containing ART for HIV-HBV. Our 
finding that two-thirds of patients achieved HBV VS by 1 year is similar to findings from another study in 
the region and one in the US.29,30 Longer follow-up of HBV VL may be needed to document full HBV 
 VS. In a multi-center cohort of 397 HIV-HBV patients in the U.S., for example, the median time to HBV 
VS was 28 months (IQR, 13-71).31 In the Netherlands, the proportion of HBV-infected patients 
suppressed on ART increased over time from 31% to 70% for HBeAg-positives and 47% to 85% for 
HBeAg-negatives.32 In Zambia, we also demonstrated an association between drug adherence and 
HBV VS which is important not only in HIV-HBV coinfection but also in CHB. Although it was not 
observed in our study, HIV VS, another marker of adherence, predicted HBV VS among 133 HIV-HBV 
patients on TDF-containing ART in the U.S.30 The rate of HBsAg loss (12.1%) we observed was higher 
than many reports from HIV-HBV coinfected and CHB patients in high-income countries33-35 but similar 
to the 17.6% reported by Hamers29 and lower than the 36% observed by Anderson.36 Our rate of 
HBsAg loss may be slightly over-estimated due to our use of a rapid test on whole blood which has 
lower sensitivity than serum assays.37 
   
Our study is one of the first in Africa to longitudinally assess hepatic stiffness using TE in HIV-infected 
individuals receiving ART and supports the general value of ART for liver health. These data also 
provide evidence in support of WHO recommendations for HBV-active ART for HIV-HBV coinfected 
patients. Our cohort had robust data on coinfections and comorbidities which may be liver disease co-
factors. Because the study was nested within a public ART treatment program, we believe these data 
are likely to be representative of many HIV-infected and HIV-HBV coinfected individuals in the region.      
 
The main limitation of our study was incomplete serial TE data among approximately 30% of patients. 
Those with available data tended to be healthier and as a consequence we may have under-estimated 
the prevalence of liver fibrosis in all patients starting ART. It is less likely that the analysis of risk factors 
for significant hepatic fibrosis or cirrhosis was affected by the missing data. Another limitation was our 
reliance on TE which is a good but imperfect surrogate measure of liver fibrosis and unlike newer 
versions, our TE device was not designed to assess steatosis. Time between TE measurements was 
only 1 year and, to some extent, observed changes may have reflected hepatic inflammation as well as 
fibrosis. Long-term follow-up is needed and will be pursued within our cohort. Additionally, more 
complete HIV VL data would have strengthened our ability to comment on the HIV’s impact on liver 
inflammation and immune activation. We characterized a relatively small (n=61) number of HIV-HBV 
patients, a key population at risk for cirrhosis and hepatocellular carcinoma (HCC) and acknowledge 
that more in-depth analysis of this group is warranted, including bi-annual screening for HCC. We also 
used a single positive HBsAg test at ART initiation to define HIV-HBV coinfection; therefore, some 
patients with HBsAg loss at 1 year could have had acute HBV infection that did not progress to chronic 
 infection. We think this is unlikely as only 1 of 10 patients with HBsAg loss had an elevated ALT at 
baseline consistent with acute infection.  
 
In summary, initiation of TDF-containing ART was associated with reduced liver fibrosis/cirrhosis in 
patients with HIV alone and HIV-HBV coinfection. Although the majority experienced HBV VS and 
reduction in LSM, many HIV-HBV coinfected patients had significant fibrosis/cirrhosis at 1 year on ART 
suggesting the need for further follow-up and monitoring of this at-risk group.  
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 Figure legends: 
 
Figure 1: Cohort flow diagram  
 
Figure 2: Change in liver stiffness during initial year of antiretroviral therapy among HIV-infected adults 
in Zambia, by HBV coinfection status 
 
Figure 3: Association between HIV and HBV viral suppression at 1 year on ART among HIV-HBV 
coinfected adults 
  
 Table 1: 
Baseline characteristics of HIV-infected individuals retained in care for 1 year on ART in 
Lusaka, Zambia, by HBV coinfection status 
 
 HIV alone 
(n=402) 
HIV-HBV  
coinfected (n=61) 
P 
Median age, years (IQR) 35 (30-41) 35 (29-39) 0.57 
Female sex, n (%) 221 (55.0) 28 (45.9) 0.18 
Body mass index, n (%) 
     <18.5 
     18.5-25 
     25+ 
 
44 (11.1) 
237 (59.6) 
117 (29.4) 
 
9 (14.8) 
40 (65.6) 
12 (19.7) 
 
0.26 
WHO clinical stage 3 or 4, n (%) 191 (47.8) 27 (45.0) 0.69 
Tuberculosis, n (%) 69 (17.2) 9 (14.8) 0.64 
Hazardous alcohol consumption, n (%) 155 (39.0) 33 (55.0) 0.02 
HCV coinfection, n (%) 0 0 NA 
Median CD4+ count (IQR)  244 (130-338) 235 (111-382) 0.97 
Median ALT, U/L (IQR) 18 (13-25) 23 (13-40) 0.02 
Elevated ALT, n (%) 63 (19.6) 18 (30.5) 0.01 
Median LSM, kPa (IQR) 5.0 (4.4-6.1) 5.5 (4.4-6.8) 0.04 
HBV VL, IU/ml, n (%) 
     <20 
     20-20,000 
     >20,000 
 
 
12 (20.0) 
21 (34.4) 
27 (44.3) 
 
HBV genotype, n (%) 
     A (A1) 
     E 
 
 
17 (43.6) 
22 (56.4) 
 
HBeAg reactive, n (%)  18 (36.0)  
HDV Ab positive, n (%)  2 (3.3)  
Abbreviations: HIV, human immunodeficiency virus; HBV, hepatitis B virus; IQR, 
interquartile range; WHO, World Health Organization; HCV, hepatitis C virus; ALT; alanine 
aminotransferase; LSM, liver stiffness measurement; HBeAg, hepatitis B e antigen; HDV, 
hepatitis delta virus; Ab, antibody; VL, viral load 
 
  
 Table 2: 
Factors associated with significant hepatic fibrosis or cirrhosis after 1 year on antiretroviral 
therapy 
 
 Crude odds ratio  
(95% CI) 
Adjusted odds ratio  
(95% CI) 
Age, per 10-year increase 1.34 (0.92-1.96) 1.81 (1.07-3.07) 
Sex 
     Female 
     Male 
 
Reference 
3.61 (1.58-8.26) 
 
Reference 
3.13 (1.10-8.93) 
WHO clinical stage  
     1 or 2 
     3 or 4 
 
Reference 
1.59 (0.76-3.33) 
 
 
Body mass index 
     <18.5 
     18.5-25 
     25+ 
 
Reference 
2.10 (0.48-9.24) 
1.69 (0.34-8.22) 
 
 
HBV coinfection 5.76 (2.66-12.50) 7.72 (2.89-20.57) 
Tuberculosis 0.99 (0.39-2.49)  
Hazardous alcohol consumption at 1y 1.75 (0.83-3.68)  
CD4+ count at BL, per 50 cells/mm
3 
increase 1.03 (0.92-1.16)  
HIV viral load <40 c/ml at 1y 1.09 (0.35-3.37) 0.89 (0.26-3.04) 
Abbreviations: CI, confidence interval; WHO, World Health Organization; HBV, hepatitis 
B virus; BL, baseline; HIV, human immunodeficiency 
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